PAB 0.00% 0.6¢ patrys limited

Onyx Announcement???, page-28

  1. 9,546 Posts.
    lightbulb Created with Sketch. 336
    Check out the ONYX website.
    ''Carfilzomib is a second-generation proteasome inhibitor that is being investigated as a potential treatment for patients with multiple myeloma and solid tumors. It is being studied in several clinical trials either as a single-agent or in combination with other therapies.''Are you trying to say that becuase ONYX hasnt come out and said one of their trials is with PAB'S PAT-SM6,that something is a miss,and our management are making things up?
 
watchlist Created with Sketch. Add PAB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.